Streetbeat News

RDGL

Vivos Inc

https://www.radiogel.com/

CEO

James Katzaroff

Employees

Industry

Surgical and Medical Instrument Manufacturing

Open

0.12

Mkt cap

51M

Volume

40K

High

0.13

P/E Ratio

-12.09

52-wk high

0.26

Low

0.12

Div yield

N/A

52-wk low

0.06

The FDA has granted Breakthrough Device Designation to Vivos Inc.'s RadioGel for treating solid metastatic tumors, particularly in lymph nodes associated with papillary thyroid cancer. RadioGel is an injectable brachytherapy device using yttrium-90 for localized radiation treatment. Vivos Inc. plans to expedite its IDE submission for human clinical trials in collaboration with the Mayo Clinic.

Portfolio Pulse from Javier Hasse

December 21, 2023 | 4:58 pm

Insiders at three companies have recently made notable purchases of their own company's stock. Earth Science Tech CEO Giorgio R Saumat bought 102,416 shares at $0.07 each, after the company reported a net profit for its fiscal second quarter. Vivos CEO and President Michael Korenko purchased 100,000 shares at $0.05 each, despite the stock falling 15% over the past six months. Gossamer Bio COO/CFO Bryan Giraudo acquired 200,000 shares at $0.56 each, following a price target increase from $5 to $6 by Wedbush.

Portfolio Pulse from Lisa Levin

November 15, 2023 | 2:31 pm

Insiders at Black Diamond Therapeutics, Bespoke Extracts, and Vivos have recently purchased shares in their respective companies. Black Diamond Therapeutics' 10% owner BB Biotech AG acquired 400,000 shares at an average price of $2.34. Bespoke Extracts' CEO Michael Feinsod bought 3,000 shares at an average price of $0.20. Vivos' CEO and President Micheal Korenko purchased 100,000 shares at an average price of $0.05.

Portfolio Pulse from Lisa Levin

October 20, 2023 | 12:55 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.